Because SLF is dual-listed, much of its sell-side coverage originates from Canadian banks that publish targets in Canadian dollars, while U.S. firms publish dollar-denominated figures. Converted to U.S. dollars, current targets reviewed for this analysis range from roughly $69 to about $102. The average lands near $84, consistent with the approximately $84 consensus reported by independent trackers in late 2026, though some calculations that weight the recent round of upward revisions point slightly higher.
The spread is unusually wide, and it says something about how analysts disagree. At the cautious end, SLF draws an Underweight-style rating from Barclays, whose analyst has expressed concern about valuation and growth durability. At the bullish end, firms including Jefferies, National Bank, and TD Cowen have raised targets substantially, pointing to asset-management scale and U.S. health momentum. In between, Scotiabank upgraded the shares to an Outperform-equivalent view in late October 2026, while Evercore ISI moved to a more neutral stance earlier in the year. This divergence means the $84 figure is a midpoint of opinion, not a consensus guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The stock closed near $72.93 in mid-November 2026, down from roughly $82 before third-quarter results. Reaching $84 therefore implies upside of about 15%—a substantial move that would effectively retest the stock's 52-week high of roughly $84.38.
The earnings picture explains the recent volatility. For the third quarter, underlying net income rose 9% year over year to C$1,146 million, and underlying EPS climbed 10% to C$2.05, with underlying ROE of 19.0%. However, reported net income fell 29% to C$785 million because of unfavorable interest-rate impacts and acquisition, integration, and restructuring costs tied to the GreenOak platform and the Bell Partners acquisition. Investors sold the stock on the gap between healthy underlying results and softer reported figures—an important distinction for anyone weighing the target.
Several verified factors could underpin a recovery. U.S. underlying earnings jumped 32% on strong medical stop-loss performance, and asset-management earnings grew 6%, helped by GreenOak and a modest contribution from MFS. The company's diversification across insurance and wealth businesses, a roughly 3.8% dividend yield, and a relatively low beta (around 0.8) give the shares defensive appeal. Analysts have been raising targets through 2026, and the company has signaled that favorable assumption changes should have a slightly positive effect on go-forward earnings. From what I see, these elements form a solid foundation if underlying trends hold.
The obstacles are equally real. Reported earnings remain vulnerable to market conditions—the third-quarter miss was driven by interest-rate moves and a flatter yield curve—and management expects GreenOak integration and restructuring costs to continue into 2027. Barclays' cautious rating reflects the view that valuation and growth may not justify the higher targets. A continued rise in long-term interest rates, weaker insurance experience, or slower asset-management inflows would pressure the valuation and keep the stock below its prior high.
The chart tells a clear story. The 52-week range of roughly $57 to $84 puts the $84 target essentially at the stock's prior peak, which now functions as a significant resistance level. The post-earnings decline left support near the $72–$73 area. A durable move toward $84 would likely require the shares to first reclaim the pre-earnings zone near $82 before attempting a retest of the 52-week high. The broader structure—shares well above the 52-week low but below the high—reflects a stock in a consolidation phase rather than a confirmed uptrend.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact period varies by firm. Investors weighing the $84 target should watch next quarter's earnings and guidance, any further analyst target revisions, and developments in the GreenOak and Bell Partners integrations. Interest-rate trends and the shape of the yield curve matter directly to Sun Life's reported results, while asset-management flows and U.S. health margins provide a read on underlying momentum. Currency moves between the Canadian and U.S. dollar also affect translated results for U.S.-based holders. I'm watching this closely as rates evolve.
For traders who prefer a data-driven, systematic view alongside fundamental research, Tickeron's AI Daily Buy/Sell Signals offer a complementary lens. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help investors discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. In my experience, these signals add a useful quantitative perspective when evaluating names like SLF.
The $84 target is a demanding but not outlandish bar. It represents roughly the average of current analyst price targets and coincides almost exactly with the stock's 52-week high, meaning the question is really whether Sun Life can reassert its prior peak. Support comes from resilient underlying earnings, U.S. growth, and a defensive, dividend-paying profile; the counterweights are market-sensitive reported results, ongoing integration costs, and a wide analyst range that includes outright caution. There is no guarantee the shares reach $84, but the path depends most on interest rates, execution of the asset-management buildout, and whether underlying earnings strength begins to show through in reported results.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SLF moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 19 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 56%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLF as a result. In 39 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.
The Moving Average Convergence Divergence Histogram (MACD) for SLF turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 27 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
The 10-day moving average for SLF crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 38%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
The Aroon Indicator for SLF entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SLF's RSI Oscillator exited the oversold zone, 16 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLF advanced for three days, in 153 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 45%.
SLF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is 46 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock slightly better than average.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.635) is normal, around the industry mean (1.586). P/E Ratio (12.042) is within average values for comparable stocks, (13.804). SLF's Projected Growth (PEG Ratio) (1.326) is slightly higher than the industry average of (0.465). Dividend Yield (0.039) settles around the average of (0.061) among similar stocks. P/S Ratio (1.541) is also within normal values, averaging (1.806).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. SLF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a financial conglomerate
Industry MultiLineInsurance